Biopharmaceutical company Sanofi has recently appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Committee, effective October 1st 2018.
To ensure a smooth transition with Jérôme Contamine, the company’s current position holder, he will join the company in September. Contamine is set to retire after over nine years at the helm.
Serving as Chief Financial Officer and Executive Vice-President for PSA Group, Chasseloup de Chatillon has held a number of financial positions within Europe at the Group, bringing the business back from the brink in the last decade.
“Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group,” stated Olivier Brandicourt, Chief Executive Officer at Sanofi.
“His track record of successfully driving finance across different businesses and geographies throughout his career will be of great value to lead our very experienced team around the world.
“I would like to express my thanks and gratitude to Jerome Contamine for his excellent service to Sanofi during the company’s transformation over the past decade. He has been a highly committed and trusted business partner to me and to my executive team.”
Sanofi is continuing to go through a significant restructure. From acquiring Bioverativ for $11.6bn in early 2018 in order to maintain its position within the haemophilia and blood disorder sector, its decision to purchase Ablynx further compliments the business and will advance its R&D strategy.
Chasseloup de Chatillon is set to join the industry when it is facing significant change. From increased pressures on all sides, to the emergence of escalating healthcare costs, particularly within the pharmaceutical space, he will aim to replicate previous successes by tackling such a complex sector.